Dr Melissa Lee’s Presentation at ATTD Asia 2025 Highlights the Glycemic Benefits of AID
We’d like to congratulate Dr Melissa Lee for her presentation at ATTD ASIA 2025. Dr Lee’s presentation highlighted the glycemic benefits of automated insulin delivery (AID) use for individuals currently managing their diabetes using multiple daily injections (MDI).
Many people who have transitioned to the Omnipod® 5 AID System were previously using MDI for their diabetes management. This analysis evaluated the real-world glycemic benefit of Omnipod 5 use in people with T1D and T2D previously treated with MDI.
This project involved a retrospective analysis of CGM and insulin data from US Omnipod 5 users aged ≥2y (T1D) or ≥18y (T2D) who self-reported MDI as their prior therapy at onboarding. A total of 39,328 users (83% T1D, 17% T2D) met the inclusion criteria. Median time in range (TIR; 70-180 mg/dL [3.9-10.0 mmol/L]) with AID was 65% and 69% in users with T1D ages 2-17y and ≥18y, respectively, and was 68% in users with T2D, with minimal time below range (TBR; <70 mg/dL [<3.9 mmol/L]) (Figure). Among adult users who utilized optimal system settings (Target setting: 110 mg/dl [6.1 mmol/L]), a median TIR of 79% and 81% was achieved in T1D and T2D users, respectively, and median time below range was ≤0.8% across both groups.
These real-world results in >39,000 Omnipod 5 users previously treated with MDI demonstrate the substantial glycemic benefits of automated insulin delivery use in people living with type 1 and type 2 diabetes.
Dr Melissa Lee’s Presentation at ATTD Asia 2025 Highlights the Glycemic Benefits of AID
We’d like to congratulate Dr Melissa Lee for her presentation at ATTD ASIA 2025. Dr Lee’s presentation highlighted the glycemic benefits of automated insulin delivery (AID) use for individuals currently managing their diabetes using multiple daily injections (MDI).
Many people who have transitioned to the Omnipod® 5 AID System were previously using MDI for their diabetes management. This analysis evaluated the real-world glycemic benefit of Omnipod 5 use in people with T1D and T2D previously treated with MDI.
This project involved a retrospective analysis of CGM and insulin data from US Omnipod 5 users aged ≥2y (T1D) or ≥18y (T2D) who self-reported MDI as their prior therapy at onboarding. A total of 39,328 users (83% T1D, 17% T2D) met the inclusion criteria. Median time in range (TIR; 70-180 mg/dL [3.9-10.0 mmol/L]) with AID was 65% and 69% in users with T1D ages 2-17y and ≥18y, respectively, and was 68% in users with T2D, with minimal time below range (TBR; <70 mg/dL [<3.9 mmol/L]) (Figure). Among adult users who utilized optimal system settings (Target setting: 110 mg/dl [6.1 mmol/L]), a median TIR of 79% and 81% was achieved in T1D and T2D users, respectively, and median time below range was ≤0.8% across both groups.
These real-world results in >39,000 Omnipod 5 users previously treated with MDI demonstrate the substantial glycemic benefits of automated insulin delivery use in people living with type 1 and type 2 diabetes.